Overview
1910 Genetics uses AI and computational biology to speed up drug discovery. It targets undruggable parts of the human proteome and designs small molecules and protein therapeutics. Its end-to-end platform covers target identification to lead optimization in a B2B model via partnerships with pharma companies, research institutions, and healthcare providers. The goal is to convert difficult targets into treatable diseases by delivering integrated discovery workflows and collaborating with NIH-supported projects.
Work here?Claim your company
Simplify's take
What believers are saying
- PEGASUS™ publication on January 6, 2026, strengthens scientific credibility and partner interest.
- Accenture invested October 31, 2024, expanding distribution into biopharma enterprise buyers.
- Microsoft and 1910's February 2024 agreement opens co-discovery, co-engineering, and SaaS revenue streams.
What critics are saying
- No clinical trials exist in November 2026; revenue depends on selling promises, not patients.
- Unproven platform risk remains existential if Microsoft and Accenture partnerships fail to convert.
- Only $25.7 million disclosed financing since 2021 leaves 1910 undercapitalized against Ginkgo and Recursion.
What makes 1910 Genetics unique
- 1910 pairs multimodal AI with laboratory automation, not software-only drug discovery.
- Microsoft signed a five-year commercial agreement in February 2024, validating enterprise infrastructure.
- PEGASUS™ published January 6, 2026, broadens 1910 beyond small molecules into macrocyclic peptides.
Help us improve and share your feedback! Did you find this helpful?
Funding
Notable Investors:
Grant funding comparison data is currently unavailable. We're working to provide this information soon!
Grant Funding Comparison